Osteoarthrosis Clinical Trial
Official title:
Clinical Evaluation of Condrosulf 800 mg in the Treatment of Symptomatic OA of the Hand: a 6-month, Double-blind, Placebo Controlled Study
The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg tablets vs. placebo once a day for 6 months in the symptomatic treatment of finger joint osteoarthritis. Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during the treatment with the tested product, Condrosulf®, versus placebo.
The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg tablets vs. placebo once a day for 6 months in the symptomatic treatment of finger joint osteoarthritis in 160 randomised patients. Primary endpoints: Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during the treatment with the tested product, Condrosulf®, versus placebo. Secondary endpoints are: Efficacy evaluation: Global impression of efficacy expressed by the patient and the physician (VAS), Grip strength (measured manometrically); Morning stiffness duration; Consumption of Paracetamol; Tolerability (4-point verbal scale); Adverse Events occurring during the treatment period; Other parameters:Treatment compliance; Biological markers of arthritis ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02542592 -
Effect of Methylprednisolone on Immune Signaling in Hip-arthroplasty Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02445898 -
Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02910830 -
Osteoarthritis Relationships and Tobacco " Ancillary Study Khoala "
|
N/A | |
Completed |
NCT01443975 -
Clinical Evaluation on the Use of the X-pander Device
|
N/A | |
Completed |
NCT01603017 -
Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis
|
N/A | |
Completed |
NCT02222740 -
A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain
|
Phase 2 | |
Completed |
NCT00860873 -
Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis
|
Phase 3 | |
Recruiting |
NCT02923310 -
Evaluation of Two Types of PRP in Knee Osteoarthritis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02518269 -
A 3-Arm Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty
|
N/A | |
Completed |
NCT03093038 -
Early Stability of the Delta-TT Cup With Polyethylene Insert Versus a Ceramic Insert. A RSA Study.
|
N/A | |
Completed |
NCT02967874 -
Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02341079 -
Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty
|
Phase 2/Phase 3 | |
Recruiting |
NCT05882227 -
Nursing Intervention for the Reduction of Anxiety During the Process of Primary Total Hip Arthroplasty Within the Optimized Recovery Program.
|
N/A | |
Completed |
NCT05697952 -
E1K Intra Articular(IA) Treatment for Knee Osteoarthritis
|
Phase 2 | |
Completed |
NCT01940692 -
Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA
|
Phase 2 | |
Completed |
NCT02071745 -
Navigated Total Knee Arthroplasty, the Correlation to CT Scans and Clinical Results
|
N/A | |
Completed |
NCT02332616 -
Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty
|
Phase 3 | |
Completed |
NCT02332603 -
Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty
|
Phase 3 | |
Completed |
NCT02319343 -
Effect of Methylprednisolone on Quadriceps Muscle Function in Patients Undergoing Total Knee-arthroplasty
|
Phase 3 | |
Completed |
NCT02332629 -
Effect of Methylprednisolone on Endothelial Function in Patients Undergoing Total Knee-arthroplasty
|
Phase 3 |